Denplan has launched a new upgraded version of The Denplan PreViser Patient Assessment (DEPPA) tool. DEPPA provides an instantaneous online report showing a patient’s Oral Health Score, alongside giving an evidence-based assessment of a patient's risk of future diseases such as dental caries, periodontal disease, tooth wear and oral cancer.
DEPPA first launched its innovative patient assessment tool in May 2013, marking a pivotal moment in clinical risk assessment, supporting effective communication and truly placing patients and their future oral health at the very centre of effective and preventive care.
Denplan has launched an enhanced version of DEPPA, following valued and valuable input from its Excel dentists. Denplan Excel is an advanced quality assurance programme, developed for dentists to help support clinical governance, professional regulation and excellence in patient care and communication. The upgraded version of DEPPA will contain three substantial benefits:
Commenting on the enhancements to DEPPA, Henry Clover, Deputy Chief Dental Officer at Denplan said: “We’re extremely proud of how popular the DEPPA tool has become since its launch over two and half years ago – over 50,000 patients have now benefitted from the evidence based tool, which is designed to help improve the patient experience and significantly improve their understanding of their oral health. It is also a valuable clinical decision support tool.
“We value the continued input from our member dentists, which enables DEPPA and our Excel programme as a whole to continue to develop. The upgrades to DEPPA have been trialled already and we are confident they are straightforward to implement and will significantly enhance the usability of the tool for dentists.”
DEPPA has received extremely positive feedback from both patients and dentists - 100% of dentists asked agreed that the DEPPA report is a ‘valuable patient communication aid’, while 95% agreed that comprehensive patient assessments, such as DEPPA, are becoming an essential aspect of quality dental care.*
Denplan has produced a simple guide to using the upgrade, for existing users of DEPPA, which is available alongside the main DEPPA manual. DEPPA remains free to all Excel dentists, whilst non-Excel Denplan members can benefit from unlimited use of the online system for just £90 per month (inc VAT). For more information about DEPPA or to sign up online, visit

GDPUK Ltd today announces the sale of its intellectual property assets to Cogora Group, one of the UK's leading publishers of healthcare brands, events and educational platforms.
The decision to sell GDPUK’s intellectual property forms part of a considered transition to ensure the long‑term stewardship and development of the brand and associated assets. Cogora brings a wealth of experience and expertise to support the continued evolution of the dentistry brand within its wide portfolio of market-leading healthcare publications. Its award-winning titles include Pulse, a long‑standing and widely recognised source of political news and clinical education for GPs, Nursing in Practice, Management in Practice, The Pharmacist, Pulse PCN and Healthcare Leader, as well as two secondary care publications – Hospital Healthcare Europe and Hospital Pharmacy Europe. The purchase will cement Cogora as the biggest publisher of primary care titles in the UK and allow it to bring its expertise in providing news, analysis, opinion and groundbreaking stories to GDPUK, as well as continue giving dentists and dental staff a voice through its website.
“After careful consideration, we believe that Cogora is well positioned to take GDPUK’s intellectual property forward,” said Tony Jacobs, founder, editor and publisher of GDPUK.com . “This transaction provides continuity for the professional community associated with GDPUK and creates opportunities for future growth under experienced ownership.”
Tony will continue involvement in GDPUK on a consulting basis.
GDPUK Ltd has worked to ensure an orderly transfer of the intellectual property and wishes Cogora every success in its future development.